ASX Announcement

Results of 2026 Annual General Meeting

Sydney, Australia, 6 November 2026: In accordance with ASX Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001* (Cth), the results of the Recce Pharmaceuticals Limited (**ASX:RCE, FSE:R9Q**) Annual General Meeting held today at 9:00am (AEDT) are attached.

All resolutions put to the Annual General Meeting were decided by way of poll.

This announcement has been approved for release by Recce Pharmaceuticals Board.

For personal use only

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Incentives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.

Results of Meeting

Recce Pharmaceuticals Ltd

Annual General Meeting

Friday, 06 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

For personal use only

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results	
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**	**S250U APPLICABLE**
1 Adoption of Remuneration Report	P	84,083,439 64.39%	45,635,837 34.95%	425,501	858,297 0.66%	91,514,709 66.14%	46,854,373 33.86%	425,501	-	Yes[a]
2 Election of Shareholder-Nominated Candidate - Ms. Diana Forsyth	P	61,204,064 45.47%	72,591,747 53.93%	227,353	801,075 0.60%	62,658,410 44.02%	79,684,024 55.98%	273,314	Not Carried	n/a
3 Re-election of Ms. Michele Dilizia as Director	P	77,422,245 57.52%	56,388,240 41.89%	212,679	801,075 0.60%	84,770,332 59.54%	57,606,776 40.46%	238,640	Carried	n/a
4 Election of Shareholder-Nominated Candidate - Mr. Amos Meltzer	P	46,441,739 34.55%	87,171,072 64.85%	410,353	801,075 0.60%	47,571,086 33.50%	94,448,309 66.50%	596,353	Not Carried	n/a
5 Election of Shareholder-Nominated Candidate - Dr. Jurgen Michaelis	P	47,342,857 35.15%	86,535,954 64.25%	144,353	801,075 0.59%	48,611,393 34.14%	93,784,002 65.86%	220,353	Not Carried	n/a
6 Re-election of Mr. Alistair McKeough as Director	-	Resolution withdrawn				Resolution withdrawn			-	n/a
7 Election of Shareholder-Nominated Candidate - Dr. Paul MacLeman	P	61,642,179 45.77%	72,229,632 53.63%	151,353	801,075 0.59%	69,087,273 48.51%	73,331,161 51.49%	197,314	Not Carried	n/a
8 ASX Listing Rule 7.1A Approval of Future Issue of Securities	P	75,387,029 55.99%	44,673,821 33.18%	180,092	14,583,297 10.83%	96,442,299 67.71%	45,993,357 32.29%	180,092	Not Carried	n/a
9 Ratification of Prior Issue of Placement Shares	P	54,665,785 49.09%	42,100,047 37.81%	22,361,844	14,583,297 13.10%	75,776,094 63.60%	43,364,544 36.40%	22,361,844	Carried	n/a

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results	
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**	**S250U APPLICABLE**
10 Adoption of Employee Incentive Plan	P	86,760,957 65.26%	45,323,442 34.09%	320,980	858,297 0.65%	93,671,266 66.79%	46,567,939 33.21%	815,980	Carried	n/a
11 Spill Resolution (Conditional Resolution)	P	47,663,528 36.75%	81,123,982 62.54%	1,291,066	924,498 0.71%	48,981,916 35.79%	87,890,640 64.21%	1,922,027	Not Carried	n/a

Note: (a) As more than 25% of the votes cast on Resolution 1 were against the adoption of the Remuneration Report, this constitutes a 'second strike' under section 250U of the Corporations Act 2001 (Cth), however Resolution 11, the spill resolution, was not passed.

For personal use only